RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Novo Nordisk A/S Stock

Novo Nordisk A/S Revenue 2025

Novo Nordisk A/S Revenue

355.96 B DKK

Ticker

NOVO B.CO

ISIN

DK0062498333

WKN

A3EU6F

In 2025, Novo Nordisk A/S's sales reached 355.96 B DKK, a 22.57% difference from the 290.4 B DKK sales recorded in the previous year.

The Novo Nordisk A/S Revenue history

YEARREVENUE (undefined DKK)GROSS MARGIN (%)
2030e567.8143,47
2029e523.9947,11
2028e480.0451,42
2027e460.2853,63
2026e416.5259,26
2025e355.9669,35
2024290.485,00
2023232.2684,60
2022176.9583,92
2021140.883,20
2020126.9583,51
2019122.0283,97
2018111.8384,25
2017111.784,21
2016111.7884,63
2015107.9385,00
201488.8183,60
201383.5783,08
201278.0382,74
201166.3581,03
201060.7880,78
200951.0879,56
200845.5577,81
200741.8376,59
200638.7475,26
200533.7672,82

Novo Nordisk A/S Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Novo Nordisk A/S, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Novo Nordisk A/S from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Novo Nordisk A/S’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Novo Nordisk A/S. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Novo Nordisk A/S’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Novo Nordisk A/S’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Novo Nordisk A/S’s growth potential.

Novo Nordisk A/S Revenue, EBIT and net profit per share

DateNovo Nordisk A/S RevenueNovo Nordisk A/S EBITNovo Nordisk A/S Net Income
2030e567.81 B DKK0 DKK154.13 B DKK
2029e523.99 B DKK250.51 B DKK147.54 B DKK
2028e480.04 B DKK226.69 B DKK134.69 B DKK
2027e460.28 B DKK219.46 B DKK126.69 B DKK
2026e416.52 B DKK195.07 B DKK112.56 B DKK
2025e355.96 B DKK163.96 B DKK91.85 B DKK
2024290.4 B DKK138.9 B DKK100.99 B DKK
2023232.26 B DKK104.7 B DKK83.68 B DKK
2022176.95 B DKK75.67 B DKK55.53 B DKK
2021140.8 B DKK59.36 B DKK47.76 B DKK
2020126.95 B DKK54.6 B DKK42.14 B DKK
2019122.02 B DKK53.68 B DKK38.95 B DKK
2018111.83 B DKK47.24 B DKK38.63 B DKK
2017111.7 B DKK49.28 B DKK38.13 B DKK
2016111.78 B DKK48.97 B DKK37.93 B DKK
2015107.93 B DKK46.96 B DKK34.86 B DKK
201488.81 B DKK35.13 B DKK26.48 B DKK
201383.57 B DKK31.64 B DKK25.18 B DKK
201278.03 B DKK29.47 B DKK21.43 B DKK
201166.35 B DKK22.37 B DKK17.1 B DKK
201060.78 B DKK18.89 B DKK14.4 B DKK
200951.08 B DKK14.93 B DKK10.77 B DKK
200845.55 B DKK12.37 B DKK9.65 B DKK
200741.83 B DKK8.94 B DKK8.52 B DKK
200638.74 B DKK9.12 B DKK6.45 B DKK
200533.76 B DKK8.09 B DKK5.86 B DKK

Novo Nordisk A/S stock margins

The Novo Nordisk A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novo Nordisk A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novo Nordisk A/S.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Novo Nordisk A/S's sales revenue. A higher gross margin percentage indicates that the Novo Nordisk A/S retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Novo Nordisk A/S's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Novo Nordisk A/S's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Novo Nordisk A/S's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Novo Nordisk A/S. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Novo Nordisk A/S's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Novo Nordisk A/S Margin History

Novo Nordisk A/S Gross marginNovo Nordisk A/S Profit marginNovo Nordisk A/S EBIT marginNovo Nordisk A/S Profit margin
2030e85 %0 %27.15 %
2029e85 %47.81 %28.16 %
2028e85 %47.22 %28.06 %
2027e85 %47.68 %27.52 %
2026e85 %46.83 %27.02 %
2025e85 %46.06 %25.8 %
202485 %47.83 %34.78 %
202384.6 %45.08 %36.03 %
202283.92 %42.76 %31.38 %
202183.2 %42.16 %33.92 %
202083.51 %43.01 %33.19 %
201983.97 %43.99 %31.92 %
201884.25 %42.24 %34.54 %
201784.21 %44.12 %34.14 %
201684.63 %43.81 %33.93 %
201585 %43.51 %32.3 %
201483.6 %39.56 %29.82 %
201383.08 %37.86 %30.13 %
201282.74 %37.77 %27.47 %
201181.03 %33.72 %25.77 %
201080.78 %31.08 %23.7 %
200979.56 %29.24 %21.08 %
200877.81 %27.16 %21.17 %
200776.59 %21.38 %20.37 %
200675.26 %23.54 %16.65 %
200572.82 %23.96 %17.37 %

Novo Nordisk A/S Aktienanalyse

What does Novo Nordisk A/S do?

Novo Nordisk A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Novo Nordisk A/S's Sales Figures

The sales figures of Novo Nordisk A/S originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Novo Nordisk A/S’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Novo Nordisk A/S's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Novo Nordisk A/S’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Novo Nordisk A/S stock

How much revenue did Novo Nordisk A/S generate this year?

Novo Nordisk A/S has achieved a revenue of 355.96 B DKK this year.

How much was the turnover of the company Novo Nordisk A/S compared to the previous year?

The revenue of Novo Nordisk A/S has increased by 22.57% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Novo Nordisk A/S?

The revenue of Novo Nordisk A/S is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Novo Nordisk A/S measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Novo Nordisk A/S so important for investors?

The revenue of Novo Nordisk A/S is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Novo Nordisk A/S pay?

Over the past 12 months, Novo Nordisk A/S paid a dividend of 10.41 DKK . This corresponds to a dividend yield of about 20.35 %. For the coming 12 months, Novo Nordisk A/S is expected to pay a dividend of 10.98 DKK.

What is the dividend yield of Novo Nordisk A/S?

The current dividend yield of Novo Nordisk A/S is 20.35 %.

When does Novo Nordisk A/S pay dividends?

Novo Nordisk A/S pays a quarterly dividend. This is distributed in the months of September, September, April, April.

How secure is the dividend of Novo Nordisk A/S?

Novo Nordisk A/S paid dividends every year for the past 26 years.

What is the dividend of Novo Nordisk A/S?

For the upcoming 12 months, dividends amounting to 10.98 DKK are expected. This corresponds to a dividend yield of 21.47 %.

In which sector is Novo Nordisk A/S located?

Novo Nordisk A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novo Nordisk A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novo Nordisk A/S from 4/1/2025 amounting to 1.14 DKK, you needed to have the stock in your portfolio before the ex-date on 3/31/2025.

When did Novo Nordisk A/S pay the last dividend?

The last dividend was paid out on 4/1/2025.

What was the dividend of Novo Nordisk A/S in the year 2024?

In the year 2024, Novo Nordisk A/S distributed 14.15 DKK as dividends.

In which currency does Novo Nordisk A/S pay out the dividend?

The dividends of Novo Nordisk A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Novo Nordisk A/S stock can be added to a savings plan with the following providers: ING and Consorsbank

Andere Kennzahlen von Novo Nordisk A/S

Our stock analysis for Novo Nordisk A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novo Nordisk A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.